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Abstract 
Background: Hepatic impairment is found in up to 20 % in critically ill patients. Hypoxic/ischemic hepatitis (HH) is a 
diffuse hepatic damage associated with high morbidity and mortality. Indocyanine green plasma disappearance rate 
(ICG-PDR) is an effective tool assessing liver function in acute and chronic hepatic diseases. Aim of this study was to 
evaluate the prognostic impact of ICG-PDR in comparison to established parameters for risk stratification.
Methods: Patients with HH were included in this prospective observational study and compared to cirrhosis, acute 
liver failure (ALF) and patients without underlying liver disease. ICG-PDR, measured non-invasively by finger pulse den-
sitometry, was assessed on admission and in patients with HH serially and results were compared between groups. 
Diagnostic test accuracy of ICG-PDR predicting 28-day mortality was analyzed by receiver operating characteristics 
(ROC).
Results: ICG-PDR on admission was significantly lower in patients with liver diseases than in patients without hepatic 
impairment (median 5.7 %/min, IQR 3.8–7.9 vs. 20.7 %/min, IQR 14.1–25.4 %/min; p < 0.001). ICG-PDR predicted 
28-day mortality independently of SOFA score and serum lactate in patients with underlying liver disease (HR 1.27, 
95 % CI 1.10–1.45, p < 0.001). In patients with HH, ICG-PDR was identified as best predictor of 28-day mortality which 
performed significantly better than SOFA, lactate, INR and AST over course of time (p < 0.05). Best cut-off for identifica-
tion of 28-day survivors was ICG-PDR ≥9.0 %/min 48 h after admission.
Conclusions: ICG-PDR is an independent predictor of mortality in patients with liver disease. Diagnostic test accu-
racy of ICG-PDR was superior to standard liver function parameters and established scoring systems in patients with 
HH.
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Background
Hepatic impairment is a frequent finding in critically ill 
patients. Cholestatic liver dysfunction is found in up to 
20 %, whereas hypoxic liver injury is found in up to 10 % 
of patients admitted to medical intensive care units (ICU) 
[1, 2]. Both, cholestatic as well as hypoxic liver dysfunc-
tion is associated with increased mortality [3–5]. Acute 
liver failure (ALF) is a life-threatening but rare disease, 
with an incidence of less than 10 cases/million per-
sons [6]. Acute-on chronic liver failure, defined as acute 
decompensation of cirrhosis, is characterized by rapid 
progression and high mortality rates [7].
Hypoxic hepatitis (HH), also known as ischemic hepa-
titis or shock liver, is a diffuse hepatic damage character-
ized by centrilobular liver cell necrosis associated with 
high morbidity and mortality [2, 4, 5]. HH is defined as a 
sharp increase of aminotransferase levels in an acute set-
ting of cardiac, septic or respiratory failure. HH is associ-
ated with high mortality rates up to more than 50 % [2, 
5, 8–10]. Laboratory parameters as serum aspartate ami-
notransferase level (AST), international normalized ratio 
(INR) and arterial serum lactate have been described 
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to be elevated in HH non-survivors [9]. However, there 
is still a lack of prognostic tool for risk stratification in 
patients with HH.
The fluorescent medical dye indocyanine green (ICG) 
is taken up exclusively by hepatocytes and is secreted 
unchanged into the bile. As ICG is removed solely by the 
liver without entering enterohepatic circulation, it has 
been described as an effective quantitative liver function 
test [11, 12]. Elimination of ICG represents both, hepatic 
blood flow as well as parenchymal function. ICG clear-
ance has been described for assessing liver function in 
patients undergoing liver surgery (hepatic resection in 
patients with hepatocellular carcinoma  (HCC)) as well 
as in donors and recipients of living donor liver trans-
plantation (OLT) [13–15]. Furthermore, indocyanine 
green plasma disappearance rate (ICG-PDR) has been 
evaluated as prognostic marker in patients with advanced 
liver cirrhosis [16, 17]. Recently, ICG clearance has been 
described as an effective tool for assessing portal hyper-
tension in patients with compensated liver cirrhosis [18]. 
Additionally, ICG-PDR serves as a good predictor for 
mortality in critically ill patients [12, 19–21].
However, there is a lack of data regarding ICG clear-
ance in critically ill patients with hepatic impairment. In 
particular, there are no data regarding ICG clearance in 
patients with HH available.
This study evaluates the prognostic impact of ICG-
PDR, in comparison to established parameters for risk 
stratification, in patients with HH and compares it to 
patients with ALF, decompensated liver cirrhosis or with-
out underlying liver disease at the ICU.
Patients and methods
Patients
In this observational study, impact of ICG-PDR was 
prospectively evaluated and compared to established 
parameters for risk stratification. Patients with HH were 
compared to patients with ALF or liver cirrhosis admit-
ted to the ICU and critically ill patients suffering from 
severe shock but without liver disease. Exclusion crite-
ria were age <18, pregnancy, HCC, previous OLT, pres-
ence of extracorporeal life support system, and presence 
of hyperthyroidism and iodine allergy according manu-
facturers product information. ICG-PDR was assessed 
in between therapy cycles in patients requiring renal 
replacement therapy (RRT).
Data collection was performed on daily basis. Sequen-
tial Organ Failure Assessment (SOFA) [22], Simplified 
Acute Physiology Score II (SAPSII) [23], Model of End-
stage Liver Disease (MELD) [24] were calculated on 
ICU admission as well as 24 and 48 h thereafter. MELD 
score was calculated for patients with HH and controls 
as well. However, MELD score is routinely used mainly in 
patients with cirrhosis and ALF. Shock index (SI) was cal-
culated as ratio of heart rate and systolic blood pressure 
as established representative of systemic hemodynam-
ics [25]. Vasopressor support and dosage were recorded. 
28-day mortality was prospectively assessed.
The study protocol was approved by the Ethics Com-
mittee of the Medical University of Vienna and per-
formed according to the ethical principles of the revised 
Helsinki declaration. Patients’ informed consent was 
obtained.
Definitions
Diagnosis of HH was made according the well-estab-
lished criteria: (a) setting of cardiac, circulatory or res-
piratory failure, (b) dramatic but transient elevation in 
serum AST levels to at least 20-fold the upper limit of 
normal, (c) exclusion of other putative causes of liver cell 
necrosis (viral or drug induced hepatitis) [8]. Patients 
with HH accompanying cirrhosis were excluded from the 
study.
Liver cirrhosis was diagnosed by histological or by 
combination of clinical signs and laboratory findings or 
by typical radiologic signs in abdominal ultrasonography 
or computed tomography scan.
Acute liver failure was defined according to the interna-
tional consensus as INR >1.5 and the presence of hepatic 
encephalopathy in patients without liver cirrhosis and 
duration of the disease (jaundice) of less than 26  weeks 
[26].
Measurement of ICG‑PDR
For each measurement ICG (0.25 mg/kg bodyweight) was 
injected intravenously via a central line followed by 5 ml 
of normal saline, as described elsewhere [27]. Plasma dis-
appearance rate of ICG was measured non-invasively by 
using a finger pulse densitometry system (LiMON, Pul-
sion Medical Systems SE, Munich, Germany) [28] (nor-
mal range of ICG-PDR is 18–25  %/min). ICG-PDR was 
assessed in all patients on admission and in patients with 
HH serially on a daily basis until day 5. ICG measure-
ment was not possible due to poor peripheral perfusion 
as consequence of severe shock in two patients with HH.
Management
Patients with septic or cardiogenic shock were treated 
according to standardized protocols [29, 30]. Intrave-
nous fluid administration as well as vasopressor therapy 
was initiated in patients meeting shock criteria aiming to 
maintain a mean arterial blood pressure of >65  mmHg. 
Early initiation of broadspectrum antibiotic treatment 
was performed according standardized protocols [29]. 
Antimicrobial therapy was adapted to culture results. 
RRT was performed in patients with renal failure and/
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or metabolic acidosis. Patients with suspected acetami-
nophen-associated ALF received intravenous N-acetyl-
cysteine [31].
Data analysis and statistics
Data were described as median and 25–75 % interquar-
tile range (IQR). Metric variables were compared using 
Mann–Whitney U test and dichotomous variables were 
compared using Chi-square analysis. Correlation analysis 
was performed using Spearman’s correlation. Cox regres-
sion proportional hazard analysis was performed to 
assess predictors of 28-day mortality. A forward stepwise 
procedure was used to identify most potent predictors.
The overall diagnostic test accuracy of ICG-PDR, 
SOFA, arterial serum lactate, AST levels and INR was 
assessed by receiver operating characteristics (ROC) 
expressed as their area under the curve (AUROC). We 
compared AUROCs at several time points using stand-
ard non-parametric methods. Estimates of diagnostic test 
accuracy (sensitivity, specificity) were calculated using 
standard methods. One-way repeated/multiple measured 
analysis of variance (ANOVA) was performed in patients 
with HH surviving until day 5. A Greenhouse-Geisser 
correction was used for sphericity. For data management 
and analyses, we used MS Excel 2008 for Mac, SPSS 21 
for Mac (SPSS, Inc. Chicago, IL, USA), and Stata 12 for 
Mac (Stata Corp., College Station, TX, USA). All p val-




A total of 97 patients were included in this observational 
study.
This cohort comprised 52 patients with HH, 35 patients 
with cirrhosis admitted to the ICU because of acute 
decompensation and 10 patients with ALF.
Main reasons for occurrence of HH were cardiogenic 
(n  =  32) and septic n  =  20) shock. Only the first epi-
sode of HH that occurred during the stay at the ICU was 
assessed in this study.
Cause of ALF was acetaminophen intoxication (n = 3), 
non-acetaminophen drug induced (n = 2), or occurred as 
consequence of viral hepatitis (n = 2) and unknown rea-
sons (n = 3).
The most common cause of cirrhosis was alcoholic 
liver disease (n = 18), followed by viral hepatitis (n = 12) 
and others (n = 5). The main ICU-admission diagnosis in 
patients with cirrhosis was sepsis/septic shock (n =  14) 
followed by coma hepaticum/hepatic encephalopathy 
grade 3–4 (n = 11) and hemorrhagic shock due to gastro-
intestinal bleeding (n = 10).
The control group included 22 critically ill patients. 
Main admission diagnoses were cardiogenic (n  =  12) 
and septic (n = 10) shock without signs of severe acute 
liver injury, viral or drug induced hepatitis or cirrhosis. 
Detailed clinical characteristics of the patients are illus-
trated in Table 1.
SOFA score as well as SAPS II score on admission were 
significantly higher in patients with HH compared to cir-
rhosis and controls (p  <  0.05). MELD score was signifi-
cantly elevated in patients with HH, cirrhosis and ALF in 
comparison to control patients (p < 0.001). Vasopressor 
support and hemodynamics were comparable between 
controls and patients with HH as shown in Table 1. ICG-
PDR did not correlate with SI, norepinephrine or dobu-
tamine dose neither in the overall group of patients with 
underlying liver disease (spearman’s r  =  0.03, p  =  n.s.; 
r = 0.01, p = n.s.; r = 0.17, p = n.s.) nor in patients with 
HH (spearman’s r = 0.09, p = n.s.; r = −0.08, p = n.s.; 
r = 0.15, p = n.s.), respectively. Furthermore, ICG-PDR 
did neither correlate with CVP (central venous pressure) 
(spearman’s r  =  −0.1, p  =  n.s.), central venous oxygen 
saturation, (spearman’s r = 0.02, p = n.s.) nor with PaO2/
FiO2 ratio (spearman’s r = −0.1, p = n.s.).
Aminotransferase levels on admission were significantly 
higher in patients with HH in comparison to patients with 
liver cirrhosis or patients without liver disease (p < 0.001). 
Furthermore, highest arterial serum lactate levels were 
found in patients with HH and ALF. Patients with HH 
showed significantly lower serum bilirubin levels than 
patients with cirrhosis and ALF (p < 0.001). ICG-PDR cor-
related with bilirubin in the overall cohort of patients with 
underlying liver disease as well as in patients with HH 
(spearman’s r = −0.47, p < 0.001; r = −0.48, p < 0.001). 
Detailed laboratory data are illustrated in Table  2. 
Median ICU length of stay was 9 days (IQR 4–15 days), 
whereas median hospital length of stay was 13 days (IQR 
6–27 days). One patient with ALF underwent OLT.
ICG‑PDR on admission and outcome in critically patients 
with liver diseases
ICG-PDR on admission was significantly lower in 
patients with liver diseases (HH, liver cirrhosis, ALF) 
than in the control group without hepatic impairment 
(median 5.7  %/min, IQR 3.8–7.9 vs. 20.7  %/min, IQR 
14.1–25.4 %/min; p < 0.001) as illustrated in Fig. 1.
There was no significant difference of ICG-PDR 
between HH and ALF. Detailed data of ICG-PDR is 
shown in Table 2.
ICG-PDR was significantly higher in 28-day survi-
vors compared to non-survivors in the overall group of 
patients with liver disease (median 6.6 %/min, IQR 4.8–
9.1  %/min vs. median 4.9  %/min, IQR 3.4–6.6  %/min; 
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p  <  0.001) as well as in the group of patients with HH 
(median 8.6 %/min, IQR 6.3–10.5 %/min vs. median 5.4, 
IQR 3.5–7.2 %/min, p < 0.001).
Univariate cox regression analysis detected a significant 
association of ICG-PDR, SOFA score and arterial serum 
lactate on admission with 28-day mortality (HR 1.31, 
95  % CI 1.15–1.50, p  <  0.001; HR 1.12, 95  % CI 1.04–
1.19, p < 0.001; HR 1.12, 95 % CI 1.07–1.18, p < 0.001) in 
patients with liver disease. In contrast, there was no asso-
ciation of age, sex, aminotransferase levels, INR and bili-
rubin levels with 28-day mortality. ICG-PDR remained 
an independent predictor of 28-day mortality even after 
Table 1 Patient characteristics
Data are shown as median and IQR or as number and percentage
a p < 0.05 HH vs. ALF
b p < 0.05 HH vs. cirrhosis
c p < 0.05 HH vs. control
d p < 0.05 ALF vs. cirrhosis
e p < 0.05 ALF vs. control
f p < 0.05 cirrhosis vs. control
Patients with liver disease HH ALF Cirrhosis Control
Parameter
 n 97 52 10 35 22
 Male, (%) 61 (63) 34 (65) 4 (40) 23 (66) 16 (73)
 Age, yearsa, b, e 54 (44–66) 64 (47–76) 40 (35–49) 48 (39–57) 53 (44–67)
 SOFAb, c 12 (8–16) 13 (9–16.8) 9 (5.8–14) 11 (7–14) 10.5 (7–13)
 SAPS IIa, b, c 57 (38–71) 60.5 (43.3–78.5) 26.5 (15.8–56.5) 51 (35–67) 50 (36–59)
 MELDa, c, d, e, f 22 (17–30) 21.5 (15–28.8) 31 (24.5–35.3) 19 (17–30) 8 (6–14.5)
 Mechanical ventilation, (%)e, f 75 (77) 42 (81) 7 (70) 26 (74) 21 (96)
 Vasopressor, (%)a 74 (76) 45 (87) 4 (50) 24 (69) 17 (77)
 Mean arterial pressure, mmHg 72 (65.5–83.5) 71.5 (68.3–77) 75.5 (66.8–88.3) 70 (65–80) 72 (65.5–83.5)
 Heart rate, beat/min 94 (80–111.5) 95 (83–113.8) 93.5 (83.3–105) 92 (80–113) 90 (76.8–105)
 Renal replacement therapy, (%) 39 (40) 21 (40) 6 (60) 12 (34) 5 (23)
 28-day mortality, (%)a, d 48 (49) 27 (52) 1 (10) 20 (57) 7 (32)
Table 2 Laboratory characteristics
Data are shown as median and IQR
AST aspartate aminotransferase level, ALT alanine aminotransferase level, INR international normalized ratio
a p < 0.05 HH vs. ALF
b p < 0.05 HH vs. cirrhosis
c p < 0.05 HH vs. control
d p < 0.05 ALF vs. cirrhosis
e p < 0.05 ALF vs. control
f p < 0.05 cirrhosis vs. control
Patients with liver disease HH ALF Cirrhosis Control
Parameter
 n 97 52 10 35 22
 ICG-PDR, %/minb, c, e, f 5.7 (3.8–7.9) 7 (4.7–8.9) 5.7 (4.8–8.0) 4.1 (3.4–5.9) 20.7 (14.1–25.4)
 Bilirubin, mg/dla, b, c, e, f 3.7 (1.7–9.7) 2.2 (0.8–3.8) 23.8 (9.1–29.2) 7.7 (3.3–16.6) 0.8 (0.6–1.3)
 INRa, c, d, e, f 1.8 (1.5–2.3) 1.7 (1.4–2.3) 3.3 (2.1–5.2) 1.7 (1.4–2.2) 1.2 (1.1–1.3)
 AST, U/lb, c, d, e 1096 (133–3798) 2667 (1267–5015) 1815 (216–5289) 84 (55–202) 67 (38–418)
 ALT, U/lb, c, d, e 743 (76–2119) 1430 (871–2417) 2224 (202–6173) 43 (24–93) 54 (21–176)
 Lactate, mmol/lb 3.5 (2–6.2) 4 (2.3–9.3) 4 (2.3–5.3) 2.5 (1.8–4) 3 (1.8–3.6)
 Creatinine, mg/dla, c 1.5 (1–2.4) 1.7 (1.3–2.3) 0.9 (0.7–1.5) 1.2 (0.8–3.1) 1.1 (0.8–2)
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correction with SOFA score and arterial serum lactate 
in multivariate cox regression model (HR 1.27, 95  % CI 
1.10–1.45, p  <  0.001). ROC analysis revealed that ICG-
PDR had the highest prediction of 28-day mortality, fol-
lowed by arterial serum lactate and SOFA (Table 3).
ICG‑PDR and outcome in patients with hypoxic hepatitis
ICG-PDR had highest AUROC of all parameters assessed 
on admission in regard to 28-day mortality as shown in 
Fig. 2. 48 h after admission, AUROC of ICG-PDR was sig-
nificantly higher than AUROC of SOFA, arterial serum 
lactate, INR and AST (p < 0.05; see Table 4). AUROC of 
Δ-ICG as increase of ICG-PDR from admission to 48 h 
value was 0.85.
Youden index showed best discrimination of 28-day 
survivors and non-survivors at a cut-off of ICG-PDR 
≥7.8 %/min on admission (sensitivity of 68 %, specificity 
of 85 %) and ≥9.0 %/min 48 h after admission (sensitivity 
79 %, specificity 100 %).
Change of ICG-PDR over time in 30 patients with HH 
is illustrated in Fig. 3. One way repeated measured analy-
sis of variance (ANOVA) showed a significant effect of 
ICG-PDR over time in 28-day survivors (Greenhouse-
Geisser corrected F = 22.4, df = 2.5, p < 0.001) but not in 
28-day non-survivors (p = n.s.).
Discussion
Hepatic impairment by means of cholestatic or hypoxic 
liver disease is of pivotal prognostic relevance in criti-
cally ill patients. In particular, HH seems to contribute 
to dramatically high mortality rates [2, 4, 5, 8, 9]. Beside 
laboratory parameters, different quantitative liver func-
tion tests such as ICG clearance or maximal liver func-
tion capacity test (LiMAx) or tests for evaluation of 
hepatic blood flow (galactose clearance) aim to facili-
tate assessment of liver function in acute and chronic 
hepatic impairment [4, 32, 33]. ICG-PDR is reported 
Fig. 1 ICG-PDR on admission in different liver disease entities. 
HH, liver cirrhosis, ALF vs. patients without hepatic impairment 
(median 5.7 %/min, IQR 3.8–7.9 vs. 20.7 %/min, IQR 14.1–25.4 %/min; 
p < 0.001). Box plot marks median, interquartile ranges and extreme 
values. HH hypoxic hepatitis, ALF acute liver failure
Table 3 ROC analysis of  various parameters assessed 
on  ICU admission for  prediction of  28-day mortality 
in patients with underlying liver disease
AST aspartate aminotransferase level, INR international normalized ratio
a AUROC p < 0.05 ICG-PDR, Lactate vs. Bilirubin, AST
b AUROC p < 0.05 SOFA vs. AST








Fig. 2 ROC predicting 28-day mortality in patients with HH a on 
admission and b 48 h after admission. AST aspartate aminotransferase 
level, INR international normalized ratio
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as prognostic parameter in stable patients with cir-
rhosis and in critically ill patients without underlying 
liver disease [17–21]. The LiMAx test was described as 
prognostic marker in liver transplant candidates as well 
as in patients with sepsis-related liver failure [32, 33]. 
However, none of the quantitative liver function tests 
were evaluated in the setting of acute hypoxic liver injury. 
Therefore, this study evaluates the prognostic impact of 
ICG-PDR in critically ill patients with HH compared to 
other forms of acute and chronic liver failure.
We could demonstrate that the degree of reduced ICG-
PDR was comparable in patients with HH and patients 
with ALF. In contrast, control patients with similar sever-
ity of shock without evident hepatic impairment had sig-
nificantly higher ICG-PDR. ICG-PDR levels in critically 
ill patients with cirrhosis were consistent with previous 
studies [17].
Furthermore, we could demonstrate a strong asso-
ciation of ICG-PDR with 28-day mortality in critically 
ill patients with liver disease. Best prediction of 28-day 
mortality was found in patients with HH. Addition-
ally, diagnostic test accuracy of ICG-PDR was increas-
ing over time in patients with HH. 48 h after admission 
ICG clearance performed significantly better than SOFA 
score, arterial serum lactate, INR or AST in prediction 
of 28-day mortality. A previous study identified INR as 
well as SOFA score as independent predictors for overall 
mortality in patients with HH [9]. Diagnostic test accu-
racy of ICG-PDR was superior compared to standard 
liver function parameters as well as SOFA score in our 
cohort. Furthermore, the dynamics of ICG-PDR over 
time demonstrated that ICG clearance did not increase 
over the course of time in patients that died within the 
first 28  days, whereas a constant increase was observed 
Table 4 ROC analysis for  predicting 28-day mortality 
in patients with HH
AST aspartate aminotransferase level, INR international normalized ratio
a AUROC p < 0.05 24-ICG-PDR vs. 24-INR
b AUROC p < 0.05 48-ICG-PDR vs. 48-Lactate, 48-SOFA, 48-INR, 48-AST
















Fig. 3 Time course of ICG-PDR in patients with HH. ICG-PDR measurement on 4 consecutive days after admission in 30 patients with HH that sur-
vived until day 5. Repeated measures ANOVA showed a significant effect of time of ICG-PDR in 28-day survivors (p < 0.001)
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in survivors (see Fig.  3). Therefore, assessment of ICG-
PDR during the course of the disease seems to be of par-
ticular prognostic relevance. 28-day survivors could be 
identified using a cut-off ICG-PDR ≥9.0 %/min 48 h after 
admission with sensitivity of 77 % and specificity 100 %.
ICG clearance is frequently used as global marker of 
hepatic function as it illustrates hepatic purification and 
also hepatic blood flow [11]. ICG-PDR did not correlate 
with SI, CVP, norepinephrine or dobutamine dose, respec-
tively. Furthermore, the control group of our cohort with 
comparable etiology and severity of shock but without 
HH or any other cause of acute or chronic liver dysfunc-
tion had significantly higher ICG-PDR levels, indicating a 
strong association of ICG-PDR and hepatic function also 
in patients with severe shock. This is in accordance with 
another study that observed no association of alterations 
of cardiac output and a change in flow-dependent hepatic 
function with respect to ICG-PDR in critically ill patients 
without clinical manifestation of hepatic impairment [34].
There are some limitations of our study. First, the sam-
ple size of our study was rather small. However, this is the 
first prospective study investigating the prognostic impact 
of ICG-PDR in critically ill patients with life-threatening 
acute and chronic liver diseases. Second, this study was 
conducted at a medical ICU of a university hospital. Thus, 
conclusions drawn in this study may not be generalizable to 
patients treated in surgical or tertiary care hospital wards.
Conclusions
In summary, we could demonstrate that ICG-PDR is a 
strong and independent predictor of 28-day mortality in 
critically ill patients with underlying liver disease. Diag-
nostic test accuracy of ICG-PDR was superior to standard 
liver function parameters and well-established scoring sys-
tems in patients with HH, which increased over course of 
time. ICG-PDR seems to be a bedside feasible non-inva-
sive tool for early risk stratification in patients with HH.
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